The origin of trimethylamine-N-oxide (TMAO) and its role in development of atherosclerosis

Zouyan He and Zhen-Yu Chen*

Food & Nutritional Sciences Programme, School of Life Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China

*Corresponding author: Zhen-Yu Chen, School of Life Sciences, The Chinese University of Hong Kong, Shatin, NT, Hong Kong, China.

Tel: (852) 3943-6382; Fax: (852) 2603-7246; E-mail: zhenyuchen@cuhk.edu.hk

DOI: 10.31665/JFB.2018.2138

Received: April 05, 2018; Revised received & accepted: May 22, 2018


Abstract

Cardiovascular disease (CVD) is a leading cause of deaths and is a growing epidemic worldwide. Atherosclerosis, the primary cause of heart diseases and stroke, is associated with vascular inflammation and accumulation of lipids and fibrous elements in the arteries. Recently, blood trimethylamine-N-oxide (TMAO) has been identified as an independent risk factor for CVD in humans. TMAO is mainly derived from dietary trimethylamine (TMA)-containing nutrients via the bioconversion of gut microbiota and hepatic flavin monooxygenases (FMOs). Both in vivo and in vitro studies have revealed that TMAO promotes atherogenesis by exacerbating vascular inflammation, impairing vascular functions and disturbing cholesterol homeostasis at multiple levels. This review summarizes the current research on the microbiota-dependent generation pathway of TMAO, the associations of TMAO with atherosclerosis, and the potential dietary intervention strategies to reduce the TMAO-associated risk of CVD.

Keywords: Cardiovascular diseases; Inflammation; Flavin monooxygenases; Trimethylamine-N-oxide; trimethylamine.

1. Introduction

Cardiovascular disease (CVD) has become an evolving epidemic and is the number one killer in the world (Benjamin et al. 2017). Most CVD can be attributable to atherosclerosis, which is characterized by narrowing or blockage of large arteries (Lusis 2000). Dyslipidemia, cigarette smoking, hypertension, obesity, diabetes as well as family history have been well-recognized as the major risk factors for CVD (Wilson et al. 1998). Recently, blood trimethylamine-N-oxide (TMAO) has also been identified as an independent risk factor for atherosclerosis (Wang et al. 2011). TMAO is a colorless and odorless amine oxide with a molecular mass of 75.1 Da (Velasquez et al. 2016). It is known as an osmoregulatory compound in marine fish to adjust buoyancy, protect against the adverse environmental stress in deep ocean, and stabilize protein structure (Withers et al. 1994; Gillett et al. 1997; Yancey 2005). In humans, a positive correlation has been found between elevated blood TMAO levels and increased risk in CVD (Wang et al. 2011; Tang et al. 2013). TMAO, which links diet, gut microbiota, and host metabolism to development of atherosclerosis, has been a hot research focus in this decade (Hill et al. 2017). This review aims to discuss (i) the microbiota-dependent production of TMAO from dietary sources, (ii) the pathological activity of TMAO in the development of atherosclerosis and CVD, and (iii) the possible dietary intervention strategies for the prevention and treatment of TMAO-related atherogenesis.

2. Origin and metabolism of TMAO

TMAO is a colorless and odorless amine oxide with a molecular mass of 75.1 Da (Velásquez et al. 2016). It is known as an osmoregulatory compound in marine fish to adjust buoyancy, protecting against the adverse environmental stress in deep ocean, and stabilize protein structure (Withers et al. 1994; Gillett et al. 1997; Yancey 2005). In humans, a positive correlation has been found between elevated blood TMAO levels and increased risk in CVD (Wang et al. 2011; Tang et al. 2013). Most TMAO in blood is derived from dietary trimethylamine (TMA)–containing nutrients including choline, phosphatidylcholine, L-carnitine and betaine (Wang et al. 2011; Koeth et al. 2013). After ingestion, gut microbes liberate the TMA moiety from the TMA-containing nutrients in the intestine. Most TMA in the intestine is passively absorbed into portal circulation and is then oxidized to produce TMAO by flavin monooxygenases (FMOs) in the liver (Zeisel and Warrier 2017). In humans, blood TMAO is mainly eliminated through urine as well as sweat and breath (Bain et al. 2005; Taesuwan et al. 2017).
He et al. TMAO-induced risk of cardiovascular diseases

2.1. Dietary sources of TMAO

TMA-containing nutrients exist in a wide range of foods such as red meat, liver, eggs, and dairy products and are the primary precursors of blood TMAO. It has been reported that administration of 8-oz sirloin steak (containing estimated 180 mg of L-carnitine) or two hard-boiled eggs with yolk (each containing approximately 250 mg of choline) could increase plasma TMAO levels when the intact gut microbiota is present (Tang et al. 2013; Koeth et al. 2013). Consumption of more than two eggs could raise both plasma and urine TMAO concentrations with about 14% of choline in eggs being converted to TMAO (Miller et al. 2014). Oral administration of γ-butyrobetaine, a metabolite from dietary L-carnitine, was reported to raise plasma TMA and TMAO concentrations in mice in a microbiota-dependent manner (Koeth et al. 2014).

Marine fish is another notable dietary source of TMAO. The TMAO content in the muscles of marine teleosts, skates, shrimps and crabs is 22–299 mmol/kg (1.7–22.5 g/kg), which positively correlated with the habitat depth of these marine animals (Kelly and Yancey 1999). A similar amount of approximate 40–200 mmol of TMAO (3–15 g) is detected in 1 kg of white muscle of seven teleosts (Treberg and Driedzic 2002). Svensson et al. (1994) showed that urinary TMA and TMAO levels reflected positively the recent fish intake. Moreover, after a 4-week dietary intervention in which 60% of the protein was substituted with lean-seafood, concentrations of TMAO was raised by 5.5 folds in urine, and by 2 folds in fasting serum of 20 healthy subjects (Schnedes et al. 2016). In a crossover trial involving 40 healthy young men, fish consumption yielded a greater increase in blood TMAO levels than either eggs or beef (Cho et al. 2017). However, Rohrmann et al. (2016) observed no obvious effect of dietary intake of meat, egg or fish on plasma TMAO levels, but a positive association between dairy food consumption and plasma TMAO concentrations in 271 participants.

2.2. Intestinal microbiota-dependent production of TMAO

Gut microbiota consist of trillions of commensal microorganisms residing in human intestine and play an obligatory role in the liberation of TMA moiety from dietary TMA-containing nutrients. Oral administration of broad-spectrum antibiotics abolished the production of TMAO from deuterium labeled phosphatidylcholine (d9-PC) because antibiotics inhibited the growth of gut bacteria in mice (Wang et al. 2011). Recolonization of gut microbes recovered the generation of TMAO after oral d9-PC treatment (Wang et al. 2011). Similar studies were conducted for d9-PC and deuterium labeled L-carnitine in healthy participants (Tang et al. 2013; Koeth et al. 2013), confirming the production of TMAO from dietary precursors is in a microbiota-dependent manner.

Gut microbial composition directly determines the TMA-generating capacity from dietary TMA-containing precursors. In the study of Koeth et al. (2013), individuals with an enterotype rich in the Prevotella genus had higher plasma TMAO concentrations after L-carnitine intake than did subjects with an enterotype rich in the Bacteroidetes genus. Nine strains of bacteria from human intestinal isolates, which represents two different phyla (Firmicutes and Proteobacteria) and six genera, were identified to produce TMA from choline in vitro (Romano et al. 2015). Moreover, it was reported that high-TMAO producers had a less diverse gut microbiome and a higher Firmicutes-to-Bacteroidetes ratio (around 2:1), than those of low-TMAO producers whose Firmicutes-to-Bacteroidetes ratio was about 1:1 (Cho et al. 2017). In contrast, in mice with an oral administration of L-carnitine, plasma TMAO level was found to be positively correlated with Bacteroidetes and negatively correlated with Firmicutes (Zhao et al. 2018). In addition, two clusters of genes CutC/D and CntA/B, were identified as the pivotal genes for the microbial production of TMAO from choline and L-carnitine, respectively (Craciun and Balskus 2012; Zhu et al. 2014). Therefore, modulating the intestinal microbial community or targeting at the microbial genes related to TMA production may become a potential therapeutic approach to prevent the TMAO-associated CVD.

2.3. Conversion of TMA to TMAO by flavin monooxygenases (FMOs) in the liver

Hepatic oxidation catalyzed by FMOs is necessary for the conversion of TMA to TMAO. Six functional FMOs (FMO1, 2, 3, 4, 5 and 6) have been identified in humans (Hernandez et al. 2004).
In human liver, FMO3 is the major adult isoform of FMOs and its expression switches on after birth (Koukouritaki et al. 2002). Interestingly, females have a higher hepatic FMO3 expression than males (Bennett et al. 2013). Veeravalli et al. (2017) reported that the most amount of TMAO was produced by hepatic FMO3 in female mice. In contrast, most amount of TMAO was derived from the action of FMO1 in male mice which lack hepatic FMO3. This sexual dimorphism of FMO3 expression was affected by sexual hormones based on the observations that androgen showed repressive while estrogen exhibited inductive effects on FMO3 expression in mice (Bennett et al. 2013). Defect in hepatic FMO3 expression results in trimethylaminuria or fish-odor syndrome, due to excessive accumulation of the odorous TMA which could be secreted in the urine, breath or sweat (Dolphin et al. 1997). Apart from its critical role in TMAO production, FMO3 was shown to be involved in the modulation of glucose and lipid homeostasis, hepatic cholesterol and triacylglycerol metabolism, and development of obesity (Shih et al. 2015; Warrier et al. 2015; Schugar et al. 2017).

3. High correlation between circulating TMAO and CVD in humans

A positive correlation between circulating TMAO and CVD risk was first revealed in the study of Wang et al. (2011). By using untargeted metabolomics analyses, plasma TMAO, choline and betaine were identified as markers to predict the increased risk for CVD in humans in an initial learning cohort and a subsequent independent validation cohort (Wang et al. 2011). These three molecules showed dose-dependent associations with CVD in a larger independent validation cohort study (N = 1,876) (Wang et al. 2011). Since then, the relationship between blood TMAO levels and risk of CVD has become an emerging area of research. Consistent with the findings of Wang et al. (2011), many studies have reported that elevated blood TMAO concentration is associated with increased CVD risk. In a 3-year cohort study involving 4,007 patients who underwent coronary angiography, plasma TMAO levels were found to be positively correlated with the risk of incident major adverse cardiovascular events (MACE) including myocardial infarction, stroke, and death (Tang et al. 2013). A similar positive correlation was observed between high plasma levels of choline and betaine with incident MACE risk in another 3-year follow-up in 3,903 subjects with elective diagnostic coronary angiography (Wang et al. 2014). However, this correlation existed only when increased plasma TMAO was present (Wang et al. 2014). In a multiethnic population-based study with 99 CVD cases and 193 unmatched control individuals, plasma TMAO concentrations significantly associated with prevalent CVD, even after adjusted for diabetes status, meat, fish and cholesterol intake (Mente et al. 2015). But no significant association was found between plasma L-carnitine levels and prevalent CVD (Mente et al. 2015). Besides, elevated plasma TMAO levels were also observed in patients with chronic heart failure and were associated with advanced left ventricular diastolic dysfunction and poorer long-term adverse clinical outcomes (Tang et al. 2015b; Troscid et al. 2015). In patients with coronary artery disease, increased plasma TMAO levels were reported to be strongly associated with heavier atherosclerotic burden and higher long-term mortality risk (Senthong et al. 2016a, 2016b). Moreover, high plasma betaine and TMAO concentrations were shown to be markers of cardiovascular risk in diabetic patients, whereas low plasma betaine concentrations suggested the increased risk of CVD in the absence of diabetes (Lever et al. 2014). Similarly, it was reported that increased serum TMAO levels correlated with increased carotid intima-media thickness (cIMT), an early hallmark of atherosclerosis, independent of conventional cardiovascular risk markers including insulin resistance, visceral obesity and fatty liver in subjects at risk for type II diabetes (Randrianarisoa et al. 2016). Furthermore, Zheng et al. (2016) observed that higher dietary consumption of phosphatidylcholine was associated with increased all-cause and CVD mortality in the US population, especially for diabetic patients.

Nevertheless, controversial results regarding the correlation between dietary intake of TMAO-containing components and CVD risk were reported in some other studies. In a study involving 14,430 middle-aged men and women, no association was found between dietary choline intake and incident coronary heart disease (Bidulescu et al. 2007). A meta-analysis of 13 controlled trials (N = 3,629) revealed that compared with placebo or control, oral L-carnitine intake was associated with a 27% reduction in all-cause mortality, a 65% reduction in ventricular arrhythmias and a 40% reduction in angina symptoms in patients experiencing an acute myocardial infarction (DiNicolantonio et al. 2013). Consistently, although an oral L-carnitine supplement (900 mg/d) raised plasma TMAO and TMAO levels, it lowered the plasma markers of vascular injury and oxidative stress, exhibiting vasculoprotective activity in hemodialysis patients (Fukami et al. 2015). In addition, among 3,942 African-American participants in Jackson Heart Study, dietary choline intake was negatively correlated with the incidence of ischemic stroke, while higher dietary betaine intake was associated with a nonlinear higher risk of the incidence of coronary heart disease (Millard et al. 2016).

Plasma TMAO may also correlate with some other diseases. Patients suffering from chronic kidney disease (CKD) with elevated plasma TMAO levels tended to have a higher risk for all-cause mortality (Tang et al. 2015a). In patients who have undergone a cardiovascular surgery, a higher serum TMAO concentration was associated with advanced CKD stages as well as increased number of infarcted coronary arteries (Mafune et al. 2016). Additionally, plasma TMAO was reported to be positively correlated with colorectal cancer risk among postmenopausal women (Bae et al. 2014).

4. Effects of TMAO on atherogenesis and plasma cholesterol

The causal relationship between plasma TMAO concentrations and atherosclerosis was examined in animal models. Dietary TMAO, L-carnitine or choline supplements were shown to facilitate atherogenesis with the formation of larger atherosclerotic plaques in mice in many studies (Wang et al. 2011; Koeth et al. 2013; Chen et al. 2016, 2017; Geng et al. 2017; Zhao et al. 2018). Even though TMAO-induced atherosclerosis has been investigated both in vitro and in vivo, the pathogenic mechanism still remains poorly understood. It is believed that aggravated vascular inflammation, impairments in blood vessels and disturbance in cholesterol homeostasis may contribute to the TMAO-induced atherogenesis (Figure 2).

4.1. TMAO-induced vascular inflammation

Atherosclerosis is a complex inflammatory disease characterized by accumulation of fat inside the arterial lumen (Lusis 2000). Vascular inflammation may damage the arterial intima, accelerating the progression of atherogenesis (Ross 1999). Studies have shown that TMAO is able to aggravate vascular inflammation. In the research of Seldin et al. (2016), elevation of inflammatory gene expression was observed in the aortas of LDLR-/- mice supplemented with...
1.3% of choline in drinking water. Acute intraperitoneal injection of TMAO at physiological levels induced the same inflammatory markers and activated the phosphorylation of p38 mitogen-activated protein kinase (MAPK), extracellular signal-kinase 1/2 (ERK 1/2) and p65 nuclear factor-κB (NF-κB) (Seldin et al. 2016), all of which play important roles in cellular inflammation and contributing to atherogenesis (Baker et al. 2011). These observations were recapitulated in human aortic endothelial cells (HAECs) and human vascular smooth muscle cells (Seldin et al. 2016). In addition, TMAO could induce inflammation in human umbilical vein endothelial cells (HUVECs) and aortas from ApoE−/− mice by activating the NLRP3 inflammasome, which was in part mediated through SIRT3-SOD2-mitochondrial ROS signaling pathway (Chen et al. 2017). Similar activation of NLRP3 inflammasome and down-stream IL-1β production was observed both in TMAO-treated carotid artery endothelial cells (CAECs) and in TMAO-infused C57BL/6J mice with partially ligated carotid artery (Bonni et al. 2017). Extensive inflammation was exacerbated by TMAO with evidence of elevations in pro-inflammatory gene expression and a decline in anti-inflammatory cytokine IL-10 expression in both serum and adipose tissue of high-fat-fed C57BL/6J mice supplemented with 0.2% of dietary TMAO (Gao et al. 2014, 2015).

4.2. TMAO-induced endothelial dysfunction

TMAO is also able to exert some detrimental effects on blood vessels. In the early stage of atherosclerosis, macrophages uptake the oxidized cholesterol mediated by scavenger receptors, leading to subendothelial accumulations of cholesterol-engorged macrophages, so called “foam cells” (Lusis 2000). TMAO was reported to accelerate the foam cell formation in some studies. Increased expressions of inflammatory adhesion-related genes including E-selectin, monocyte chemotactic protein 1 (MCP-1), intracellular adhesion molecule 1 (ICAM-1), and vascular cell adhesion molecule 1 (VCAM-1) were observed in the aorta of high-choline-fed LDLR−/− mice, promoting the recruitment of monocytes and their differentiation into macrophages (Seldin et al. 2016). Similarly, TMAO decreased the self-repair capacity and induced monocyte adhesion in HUVECs, which was partially contributed by the acti-
vation of PKC/NF-κB/VCAM-1 pathway (Ma et al. 2017). Besides, TMAO was reported to up-regulate the expression of macrophage receptors (CD36 and SR-A1) in ApoE\(^{-/-}\) mice fed a high-choline or high-TMAO diet (Wang et al. 2011), as well as in TMAO-treated murine macrophage J774A.1 cells (Mohammadi et al. 2016), facilitating the up-take of cholesterol into macrophage and foam cell formation. Subsequently, Geng et al. (2017) observed accelerated atherosclerotic plaque progression, promoted macrophage recruitment, higher CD36 and pro-inflammatory cytokine expression in the plaque lesions in high-TMAO-fed ApoE\(^{-/-}\) mice. They also found that TMAO-related foam cell formation was mediated, at least partially, by the CD36/EPK/MKJN pathway (Geng et al. 2017). However, in murine J447 macrophage treated with acetylated-LDL, TMAO in increasing concentrations did not alter the cholesterol uptake or efflux (Collins et al. 2016).

TMAO impairs blood vessels by augmenting thrombotic risk and causing endothelial dysfunction. It was shown that TMAO directly enhanced platelet responsiveness in mice intraperitoneally injected with TMAO or administered with a high-choline or a high-TMAO diet, resulting in increased thrombosis potential (Zhu et al. 2016). Moreover, endothelial dysfunction was induced by TMAO with an increase in the levels of serum vasoconstrictors endothelin 1 and thromboxane A\(_2\), while a decrease in the levels of serum vasodilator nitric oxide (NO) and prostaglandin I\(_2\) in high-TMAO- or high-choline-fed Kunming mice (Hu et al. 2015; Ren et al. 2016). Furthermore, TMAO treatment decreased the expression of inflammasome-dependent tight junction protein ZO-1 in endothelial cells, leading to endothelial hyperpermeability and dysfunction (Boini et al. 2017). In a senescence-accelerated mouse model, TMAO raised the expression of vascular aging-related markers, accelerated aging-related vascular remodeling and aggravated vascular dysfunction by significantly decreasing endothelial-dependent dilation capacity while increasing vascular contraction activity (Ke et al. 2018).

### 4.3. Effect of TMAO on cholesterol homeostasis

The pathogenesis of atherosclerosis is highly related to cholesterol metabolism. Research has shown that TMAO is able to disturb cholesterol homeostasis at multiple levels, including reverse cholesterol transport, de novo bile acid synthesis and excretion. In the study of Koeth et al. (2013), addition of TMAO in diet significantly reduced the reverse cholesterol transport (RCT) in ApoE\(^{-/-}\) mice by 35%. RCT is the net movement of cellular cholesterol from peripheral tissues to the liver for its excretion in the bile and ultimately the feces. Impairment of RCT is believed to aggravate the development of atherosclerosis (Rader et al. 2009). ATP cassette transporter type 1 (ABCA1) is to remove cellular cholesterol to plasma apolipoprotein A1 (Apo A1) in RCT pathway. A modest but statistically significant elevation in the mRNA level of (ABCA1) was found in the TMAO-treated peritoneal macrophages from C57BL/6j mice (Koeth et al. 2013). However, Mohammadi et al. (2016) observed elevations in both protein and mRNA levels of ABCA1 after 8 h of TMAO treatment in murine macrophage J774A.1 cell line, but no obvious alterations and significant decreases in ABCA1 expression were reported after 18 h and 24 h of TMAO treatment, respectively. In RAW264.7 macrophage, TMAO increased ABCA1-dependent cholesterol efflux to Apo A1, suggesting that the alteration in macrophage ABCA1 expression may not account for the TMAO-induced decline in RCT (Koeth et al. 2013). Moreover, TMAO conspicuously down-regulated the expression of CYP7A1, the rate-limiting enzyme in de novo biosynthesis of bile acid from cholesterol, as well as multiple hepatic transporters (including Oat1, Oat4, Mrp2 and Ntcp) for bile efflux from liver into intestine (Koeth et al. 2013). A significant smaller total bile acid pool size was observed in high-TMAO- or high-choline-fed ApoE\(^{-/-}\) mice than that of control (Koeth et al. 2013; Chen et al. 2016). As a result, less cholesterol is likely to be eliminated via bile, leading to hepatic cholesterol accumulation and atherogenesis.

High plasma cholesterol level, in particular that of low-density-lipoprotein cholesterol (LDL-C), is believed to be a major risk factor for atherosclerosis. Inconsistent results regarding the TMAO-related changes in plasma lipids have been reported. Some studies have shown that plasma total cholesterol (TC) and triacylglycerol (TG) levels were not affected by elevated plasma TMAO concentration in mice (Wang et al. 2011; Koeth et al. 2013; Hu et al. 2015; Seldin et al. 2016; Zhao et al. 2018). However, obvious increases in plasma TC or/and TG were observed in mice fed choline, a dietary precursor of TMAO, in some other studies (Chen et al. 2016; Ren et al. 2016). While declines in plasma TC and TG were reported in high-fat-fed C57BL/6j mice administered with 0.2% of TMAO in the diet (Gao et al. 2014).

### 5. Potential dietary approaches for the prevention of TMAO-induced atherosclerosis

The pathogenesis of atherosclerosis is highly related to cholesterol metabolism. Research has shown that TMAO is able to disturb cholesterol homeostasis at multiple levels, including reverse cholesterol transport, de novo bile acid synthesis and excretion. In the study of Koeth et al. (2013), addition of TMAO in diet significantly reduced the reverse cholesterol transport (RCT) in ApoE\(^{-/-}\) mice by 35%. RCT is the net movement of cellular cholesterol from peripheral tissues to the liver for its excretion in the bile and ultimately the feces. Impairment of RCT is believed to aggravate the development of atherosclerosis (Rader et al. 2009). ATP cassette transporter type 1 (ABCA1) is to remove cellular cholesterol to plasma apolipoprotein A1 (Apo A1) in RCT pathway. A modest but statistically significant elevation in the mRNA level of (ABCA1) was found in the TMAO-treated peritoneal macrophages from C57BL/6j mice (Koeth et al. 2013). However, Mohammadi et al. (2016) observed elevations in both protein and mRNA levels of ABCA1 after 8 h of TMAO treatment in murine macrophage J774A.1 cell line, but no obvious alterations and significant decreases in ABCA1 expression were reported after 18 h and 24 h of TMAO treatment, respectively. In RAW264.7 macrophage, TMAO increased ABCA1-dependent cholesterol efflux to Apo A1, suggesting that the alteration in macrophage ABCA1 expression may not account for the TMAO-induced decline in RCT (Koeth et al. 2013). Moreover, TMAO conspicuously down-regulated the expression of CYP7A1, the rate-limiting enzyme in de novo biosynthesis of bile acid from cholesterol, as well as multiple hepatic transporters (including Oat1, Oat4, Mrp2 and Ntcp) for bile efflux from liver into intestine (Koeth et al. 2013). A significant smaller total bile acid pool size was observed in high-TMAO- or high-choline-fed ApoE\(^{-/-}\) mice than that of control (Koeth et al. 2013; Chen et al. 2016). As a result, less cholesterol is likely to be eliminated via bile, leading to hepatic cholesterol accumulation and atherogenesis.

High plasma cholesterol level, in particular that of low-density-lipoprotein cholesterol (LDL-C), is believed to be a major risk factor for atherosclerosis. Inconsistent results regarding the TMAO-related changes in plasma lipids have been reported. Some studies have shown that plasma total cholesterol (TC) and triacylglycerol (TG) levels were not affected by elevated plasma TMAO concentration in mice (Wang et al. 2011; Koeth et al. 2013; Hu et al. 2015; Seldin et al. 2016; Zhao et al. 2018). However, obvious increases in plasma TC or/and TG were observed in mice fed choline, a dietary precursor of TMAO, in some other studies (Chen et al. 2016; Ren et al. 2016). While declines in plasma TC and TG were reported in high-fat-fed C57BL/6j mice administered with 0.2% of TMAO in the diet (Gao et al. 2014).

### 5.1. Modulation of gut microbial composition by probiotics and/or prebiotics

Production of TMAO from dietary TMA-containing nutrients relies on both gut microbial activities in the intestine and host FMO processing in the liver. These multiple microbial-host interactions for TMAO generation might become potential therapeutic targets to reduce the risk of TMAO-associated CVD.

Due to the critical role of gut microbes in the TMAO generation pathway, modulating intestinal microbiota composition can be a promising strategy to limit the liberation of TMA from dietary precursors. Probiotics are the alive microorganisms conferring a health benefit on host when administered in adequate amount (Sánchez et al. 2017). It was reported that probiotics could remodel intestinal microbial composition, and show protective effects in nonalcoholic fatty liver disease, obesity, diabetes, and intestinal diseases (Li et al. 2003; Delzenne et al. 2011; Gomes et al. 2014; Sánchez et al. 2017). Administration of probiotics might be able to reduce the microbiota-dependent production of TMA and TMAO. However, their effect on TMAO generation remains inconclusive. Martin et al. (2008) found that probiotic Lactobacillus paracasei supplement could decrease TMA concentration with TMAO being unchanged in the liver of mice. Meanwhile administration of another probiotics, Lactobacillus rhamnosus, raised hepatic TMAO concentrations without affecting hepatic TMA levels (Martin et al. 2008). In contrast, the multi-strain probiotic VSL\#3 (900 billion alive bacteria/day) did not influence the plasma TMAO levels, which was elevated after 4 weeks of feeding a high-fat diet in nineteen healthy, non-obese males (Boutagy et al. 2015). Similarly, 12 weeks of three times daily 6.5 × 10\(^{9}\) colony-forming units (CFU) Lactobacillus casei Shirota (LcS) administration did not alter plasma TMAO levels in patients with metabolic syndrome (Tripathi et al. 2015). Dietary intervention with prebiotics is another possible strategy to modulate intestinal microbiota composition and reduce their TMA-generating capacity. Prebiotics is defined as a selectively
fermented ingredient that can cause specific changes in the composition and/or activity of the gastrointestinal microbiota, thus conferring benefits upon host health (Valcheva and Dieleman 2016). However, the function of probiotics in the microbiota-dependent production of TMA and TMAO is largely unknown. Chen et al. (2016) reported that resveratrol, a natural phytoalexin, helped to decrease plasma TMA and TMAO levels, accompanied by development of smaller aortic atherosclerotic lesions in high-choline-fed mice. Analyses on the gut bacterial composition of mice revealed that resveratrol administration decreased the proportion of Firmicutes while it increased the proportion of Bacteroidetes (Chen et al. 2016). Moreover, resveratrol raised the relative abundances of the probiotics Lactobacillus and Bifidobacterium, resulted in elevations in the bile salt hydrolase activity, and enhancement in bile acid deconjugation and excretion in the feces (Chen et al. 2016). All these results suggest that resveratrol could be a beneficial prebiotic to alleviate the TMAO-induced atherosclerosis, in part, via gut microbiota remodeling.

Dietary probiotics and prebiotics can be promising candidates to modulate gut microbial composition and decrease the TMAO generation from dietary precursors thus preventing the development of smaller aortic atherosclerotic lesions in high-choline-fed mice. Analyses on the gut bacterial composition of mice revealed that resveratrol administration decreased the proportion of Firmicutes while it increased the proportion of Bacteroidetes (Chen et al. 2016). Moreover, resveratrol raised the relative abundances of the probiotics Lactobacillus and Bifidobacterium, resulted in elevations in the bile salt hydrolase activity, and enhancement in bile acid deconjugation and excretion in the feces (Chen et al. 2016). All these results suggest that resveratrol could be a beneficial prebiotic to alleviate the TMAO-induced atherosclerosis, in part, via gut microbiota remodeling.

5.2. Regulation of host metabolism by functional foods and nutraceuticals

Functional foods possess a specific health-benefit beyond their nutritional properties when consumed regularly, while nutraceuticals are the bioactive agents derived from foods and can be used as diet supplements for health promotion (Espin et al. 2007). To date, functional foods and nutraceuticals have been used in the prevention and treatment of atherosclerosis and CVD, especially for those people who are in the marginal risk but do not warrant medical prescriptions. Application of functional foods or nutraceuticals may potentially regulate the host metabolism and attenuate the TMAO-correlated progression of CVD. Nevertheless, research concerning the benefits of functional foods or nutraceuticals on TMAO generation pathway, the dose of probiotics/prebiotics used, and the duration of intervention needed to remodel the microbial composition in the host intestine.

6. Conclusion

Blood TMAO has recently been identified as an independent marker for CVD. Most blood TMAO is derived from dietary TMA-containing nutrients, relying on both intestinal gut microbes and host hepatic FMOs. Studies have shown that TMAO can promote atherogenesis mainly by exacerbating vascular inflammation, impairing vascular function and disturbing cholesterol homeostasis. Dietary interventions by using probiotics and/or prebiotics, as well as functional foods and nutraceuticals may offer promising strategies for the prevention and treatment of TMAO-associated CVD. However, solid evidences are still lacking. There is a pressing need to investigate the functions of these beneficial dietary components in the production of TMAO and the TMAO-induced atherogenesis.

References


Rader, D.J., Alexander, E.T., Weibel, G.L., Billheimer, J., and Rothblat, G.H. (2009). The role of reverse cholesterol transport in animals and hu-
TMAO-induced risk of cardiovascular diseases

He et al.